NIH becomes latest agency to close the book on hydroxychloroquine


The hydroxychloroquine saga may finally be coming to an end.
Earlier this week, the Food and Drug Administration pulled its emergency use authorization for the drug, heavily touted by President Trump as a bulwark against the coronavirus. A couple of days later, the World Health Organization stopped its trial of the medication's effect on COVID-19 patients. Now, the National Institutes of Health have joined the consensus, halting its own clinical trial late Friday evening. NIH apparently agreed with the other agencies that the drug is "very unlikely" to benefit patients who require hospitalization.
Per Politico, this could be the drug's "death knell," at least in a certain respect. It's been around for decades and is approved to treat malaria, arthritis, and lupus, and doctors could still use it "off label" to treat coronavirus patients, but the end of the two major studies signal that scientists will focus elsewhere in the hopes of finding a breakthrough treatment for severely ill patients. Gilead's antiviral remdesivir and a cheap steroid called dexamethasone are promising contenders. Read more at Politico.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Fake AI job seekers are flooding U.S. companies
In the Spotlight It's getting harder for hiring managers to screen out bogus AI-generated applicants
By Theara Coleman, The Week US
-
The full moon calendar for every month.
In depth When to see the lunar phenomenon every month
By Devika Rao, The Week US
-
Meta on trial: What will become of Mark Zuckerberg's social media empire?
Today's Big Question Despite the CEO's attempt to ingratiate himself with Trump, Meta is on trial, accused by the U.S. government of breaking antitrust law
By Joel Mathis, The Week US
-
New Mexico to investigate death of Gene Hackman, wife
speed read The Oscar-winning actor and his wife Betsy Arakawa were found dead in their home with no signs of foul play
By Peter Weber, The Week US
-
Giant schnauzer wins top prize at Westminster show
Speed Read Monty won best in show at the 149th Westminster Kennel Club dog show
By Peter Weber, The Week US
-
Beyoncé, Kendrick Lamar take top Grammys
Speed Read Beyoncé took home album of the year for 'Cowboy Carter' and Kendrick Lamar's diss track 'Not Like Us' won five awards
By Peter Weber, The Week US
-
The Louvre is giving 'Mona Lisa' her own room
Speed Read The world's most-visited art museum is getting a major renovation
By Peter Weber, The Week US
-
Honda and Nissan in merger talks
Speed Read The companies are currently Japan's second and third-biggest automakers, respectively
By Peter Weber, The Week US
-
Taylor Swift wraps up record-shattering Eras tour
Speed Read The pop star finally ended her long-running tour in Vancouver, Canada
By Peter Weber, The Week US
-
Drake claims illegal boosting, defamation
Speed Read The rapper accused Universal Music of boosting Kendrick Lamar's diss track and said UMG allowed him to be falsely accused of pedophilia
By Rafi Schwartz, The Week US
-
'Wicked' and 'Gladiator II' ignite holiday box office
Speed Read The combination of the two movies revitalized a struggling box office
By Peter Weber, The Week US